Cartesian Therapeutics (RNAC) Long-Term Debt Repayments (2015 - 2023)

Cartesian Therapeutics (RNAC) has reported Long-Term Debt Repayments for 5 consecutive years, with $24.9 million the latest figure, recorded in Q3 2023.

• In Q3 2023, Long-Term Debt Repayments changed N/A year-over-year to $24.9 million; the TTM figure through Dec 2024 stood at $24.9 million (changed 0.0% YoY), while the FY2023 annual figure was $27.5 million, changed N/A from the prior year.
• Long-Term Debt Repayments climbed to $24.9 million in Q3 2023 per RNAC's latest filing, from $15.1 million in the prior quarter.
• Across five years, Long-Term Debt Repayments topped out at $24.9 million in Q3 2023 and bottomed at $700000.0 in Q3 2019.
• Historically, Long-Term Debt Repayments has averaged $7.8 million across 3 years, with a median of $2.1 million in 2019.
• On a YoY basis, Long-Term Debt Repayments climbed as much as 2059.0% in 2020 and fell as far as 2059.0% in 2020.
• Cartesian Therapeutics' Long-Term Debt Repayments stood at $2.1 million in 2019, then surged by 619.67% to $15.1 million in 2020, then soared by 64.57% to $24.9 million in 2023.
• Business Quant data shows RNAC's Long-Term Debt Repayments at $24.9 million in Q3 2023, $15.1 million in Q3 2020, and $2.1 million in Q2 2020.